ESTRO 2024 - Abstract Book

S2549

Clinical - Urology

ESTRO 2024

Kirsty Nash, Fiona Birrell, Helena Belikova, David Dodds, Carolynn Lamb, Nicholas MacLeod, Stephen McKay, Azmat Sadozye, Norma Sidek, Abdulla Alhasso

The Beatson West of Scotland Cancer Centre, Radiotherapy, Glasgow, United Kingdom

Purpose/Objective:

Prostate cancer is the most common cancer for males in the UK¹. Radiotherapy continues to be a recommended treatment option for localised and locally advanced prostate cancer, however the long term impact on bowel function has been a topic of concern for many years². Although advancements in technology have limited rectal doses with the use of volumetric modulated arc techniques (VMAT), more can be done in patients with bowel sensitivity³. We evaluate patient reported toxicity in men with inflammatory bowel disease (IBD) or previous bowel surgery 1 year after radiotherapy to the prostate with the use of Hydrogel Vue rectal spacer.

Material/Methods:

Patients who completed radiotherapy with a spacer one year prior had been identified using ARIA, and patients were telephoned to discuss their experiences. Data was collated from Clinical Portal for patient characteristics, and PSA readings after one year follow up. 11 patients had 74Gy in 37 fractions resulting in 2Gy per day, and the remaining 5 patients had 3Gy per day 60Gy in 20 fraction regime. All patients underwent CT simulation with standard bowel and bladder preparation, using an enema the night before and day of the scan then drinking 500mls water waiting 30 minutes. CTV and PTV margins were contoured by clinical oncologists, along with the spacer.

Results: